Comparison and evaluation of DRI® methamphetamine, DRI Ecstasy, Abuscreen® ONLINE amphetamine, and a modified Abuscreen ONLINE amphetamine screening immunoassays for the detection of amphetamine (AMP), methamphetamine (MTH), 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA) in human urine

被引:15
作者
Stout, PR
Klette, KL
Wiegand, R
机构
[1] Aegis Sci Corp, Nashville, TN 37210 USA
[2] Naval Drug Screening Lab, Jacksonville, FL 32212 USA
关键词
D O I
10.1093/jat/27.5.265
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The performances of four immunoassays (DRI amphetamines, DRI ecstasy, Abuscreen ONLINE amphetamines, and a modified Abuscreen ONLINE amphetamines) were evaluated for control failure rates, sensitivity, and specificity for amphetamine (AMP), methamphetamine (MTH), 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA). The two DRI reagents and the ONLINE reagents were run according to manufacturer specifications using a Roche Hitachi Modular DDP system. The modified ONLINE reagent was calibrated with MDMA and had 16mM sodium periodate added to the R2 reagent. These assays were run on approximately 27,500 human urine samples and 7000 control urine samples prepared at 350 and 674 ng/mL over the course of 8 days. All assays were calibrated using a single point, qualitative cutoff standard with the manufacturer-recommended compound at the Department of Defense cutoff (500 ng/mL). Gas chromatography-mass spectrometry (GC-MS) confirmation was conducted on screened- positive samples. Control performance for the manufacturer recommended assays was excellent, with a maximum qualitative control failure rate of 2.03%. The modified ONLINE reagent demonstrated poor control performance with a maximum failure rate of 38.3% and showed no improved MDMA sensitivity when compared with the ONLINE reagent; the confirmation rate (20%) was improved when compared with the production ONLINE reagent (8%). The DRI ecstasy reagent provided improved sensitivity for MDMA as compared with the ONLINE reagent, with approximately 23% more samples screening and confirming positive for MDMA and a confirmation rate of approximately 90%. The DRI methamphetamine reagent had a low confirmation rate (6% or less) and produced numerous positives for samples with only ephedrine or pseudoephedrine present.
引用
收藏
页码:265 / 269
页数:5
相关论文
共 16 条
[1]  
BAKER DP, 1995, J FORENSIC SCI, V40, P108
[2]   Use of nonprescription weight loss products - Results from a multistate survey [J].
Blanck, HM ;
Khan, LK ;
Serdula, MK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (08) :930-935
[3]  
Broussard L A, 1997, Clin Lab Sci, V10, P83
[4]  
CASTELLON D, 2002, AIR FORCE TIMES 0425
[5]  
CLOUD J, 2000, TIME 0605
[6]   EVALUATION OF 6 COMMERCIAL AMPHETAMINE AND METHAMPHETAMINE IMMUNOASSAYS FOR CROSS-REACTIVITY TO PHENYLPROPANOLAMINE AND EPHEDRINE IN URINE [J].
DNICUOLA, J ;
JONES, R ;
LEVINE, B ;
SMITH, ML .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1992, 16 (04) :211-213
[7]   Content versus label claims in ephedra-containing dietary supplements [J].
Gurley, BJ ;
Gardner, SF ;
Hubbard, MA .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (10) :963-969
[8]   Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang) [J].
Gurley, BJ ;
Gardner, SF ;
White, TM ;
Wang, PL .
THERAPEUTIC DRUG MONITORING, 1998, 20 (04) :439-445
[9]  
JONES S, 2002, STARS STRIPES 0515
[10]  
Kintz P, 1997, J ANAL TOXICOL, V21, P589